Single-Step Method of RNA Isolation by Acid Guanidinium Thiocyanate–Phenol–Chloroform ExtractionThe transcriptional corepressor MTG16a contains a novel nucleolar targeting sequence deranged in t (16; 21)-positive myeloid malignanciesThe single-step method of RNA isolation by acid guanidinium thiocyanate-phenol-chloroform extraction: twenty-something years onA distinct epigenetic signature at targets of a leukemia protein.Novel RNA-binding properties of the MTG chromatin regulatory proteins.Derangement of a factor upstream of RARalpha triggers the repression of a pleiotropic epigenetic network.Impaired retinoic acid (RA) signal leads to RARbeta2 epigenetic silencing and RA resistance.Down-regulation of microRNAs 222/221 in acute myelogenous leukemia with deranged core-binding factor subunitsThymoglobulin prevents chronic graft-versus-host disease, chronic lung dysfunction, and late transplant-related mortality: long-term follow-up of a randomized trial in patients undergoing unrelated donor transplantation.Entrainment of breast (cancer) epithelial cells detects distinct circadian oscillation patterns for clock and hormone receptor genes.The MTG proteins: chromatin repression players with a passion for networking.Identification of an estrogen-regulated circadian mechanism necessary for breast acinar morphogenesis.Loss of MTG16a (CBFA2T3), a novel rDNA repressor, leads to increased ribogenesis and disruption of breast acinar morphogenesisTracing anti-cancer and cancer-promoting actions of all-trans retinoic acid in breast cancer to a RARα epigenetic mechanism of mammary epithelial cell fate.The intra-bone marrow injection of cord blood cells extends the possibility of transplantation to the majority of patients with malignant hematopoietic diseases.Definitions of histocompatibility typing terms: Harmonization of Histocompatibility Typing Terms Working Group.Definitions of histocompatibility typing terms.RUNX1: A microRNA hub in normal and malignant hematopoiesis.Very high frequency of hypermethylated genes in breast cancer metastasis to the bone, brain, and lung.The Rome Transplant Network model compared to the Italian Bone Marrow Donor Registry activity for unrelated donor search process and transplant efficiency for hematologic malignancy.Harnessing 3D models of mammary epithelial morphogenesis: An off the beaten path approach to identify candidate biomarkers of early stage breast cancer.miR-17 deregulates a core RUNX1-miRNA mechanism of CBF acute myeloid leukemia.Validation of the acute leukemia-EBMT score for prediction of mortality following allogeneic stem cell transplantation in a multi-center GITMO cohort.Synthesis of a resveratrol analogue with high ceramide-mediated proapoptotic activity on human breast cancer cells.Myeloid maturation block by AML1-MTG16 is associated with Csf1r epigenetic downregulation.In vivo imaging of retinoic acid receptor beta2 transcriptional activation by the histone deacetylase inhibitor MS-275 in retinoid-resistant prostate cancer cells.Resveratrol induces growth inhibition and apoptosis in metastatic breast cancer cells via de novo ceramide signaling.Mammary epithelial morphogenesis and early breast cancer. Evidence of involvement of basal components of the RNA Polymerase I transcription machinery.A registry of HLA-typed donors for production of virus-specific CD4 and CD8 T lymphocytes for adoptive reconstitution of immune-compromised patients.Role of the HLA class II: HCV-related disorders.Endogenous reactivation of the RARbeta2 tumor suppressor gene epigenetically silenced in breast cancer.Nonpermissive HLA-DPB1 disparity is a significant independent risk factor for mortality after unrelated hematopoietic stem cell transplantation.Concurrent search for unrelated cord and volunteer donor in high-risk acute lymphoblastic leukemia.Loss of MTG16a (CBFA2T3), a novel rDNA repressor, leads to increased ribogenesis and disruption of breast acinar morphogenesis.MiR-221-regulated KIT level by wild type or leukemia mutant RUNX1: a determinant of single myeloblast fate decisions that - collectively - drives or hinders granulopoiesis.Access to alternative donor hematopoietic search and transplantation for acute leukemia in different macro-regions of Italy. A GITMO/IBMDR study.Direct intrabone transplant of unrelated cord-blood cells in acute leukaemia: a phase I/II study.Undermining ribosomal RNA transcription in both the nucleolus and mitochondrion: an offbeat approach to target MYC-driven cancer.Is it time to re-think a sustainable banking model for the Italian Cord Blood Network?A repressive epigenetic domino effect confers susceptibility to breast epithelial cell transformation: implications for predicting breast cancer risk.
P50
Q25938986-9FAE4A85-3525-4CC8-BE24-5D92EA0F0AABQ28202877-5a9b1d07-44c7-796a-689a-0a79d37338a3Q28296342-e66fa594-4ecb-dc38-0810-f62e58541abfQ33271210-ebbc36be-4641-897a-4f7d-0cf13cdb836eQ33379264-97dbc97f-49a0-528b-453e-b7ff9e01dadcQ33403253-f66a5b05-4547-1aba-283e-10c68caaa3d9Q34150792-2eee90a6-4f4f-c279-bb16-2f8f57c977d9Q34300594-88be3b20-422d-0e69-8abb-08fe7a29fc9bQ34517135-1798c4e8-4e0b-9301-3e36-c10805ff0c67Q35801411-f454a01a-438f-9651-135b-291c1cf2ffcdQ35808823-f2beba4b-4d92-a2da-aa3c-ab2763d26f18Q36338782-24adbb74-44be-a035-5543-ae79ec05eb49Q37310609-5a6b34eb-480f-f58c-4c3b-6ac78d58ef78Q37699371-393d5264-4a2e-7082-12ae-f650d2dd5a69Q37788413-4b4ddd9b-41b1-a8dd-4b7f-c89b957c4c64Q37896945-4a4f0987-491a-81f4-a00d-7c51fc02faa5Q37946078-905fa5c4-4d85-178e-3831-4497272620cfQ38076281-c3de7cf1-4a29-3b81-326b-11959ffd202aQ38447859-964e4857-4096-3ca0-3758-c37f6a9b4719Q38728327-f4f6397b-4ed3-a081-5293-e584daa51b24Q38757831-00e832ec-4249-1695-3621-728251a65c99Q38917442-f731a273-46ce-aad7-6655-1c252f0d314aQ40343240-1b93b000-45c8-c713-125c-28d002cc25f7Q40357881-376e8007-4d5b-6e8d-6d96-451cdf2c92f0Q40399336-0cda8316-4626-7a04-3fdc-555ae9bbe22cQ40470869-b91e69d7-4073-8d0e-5389-720063433ba5Q40625434-a551dedb-42b6-3df8-3180-02178c80bf8aQ41113532-531c1956-44b9-0558-1de4-0dd48bead6adQ42205114-313304ac-4fdb-85da-f7a4-66113e941559Q43040474-208464fd-4856-1b37-31d9-a5fe4b56e68dQ43973979-5722209c-465f-f953-ecce-c50e606bb197Q45172988-2b03a0cf-495f-b92d-7fd0-b6f4b94385c4Q45210269-09a04886-4c69-f1c5-acc3-52ec49b797d2Q46203613-b27e1f71-48cd-287d-2522-6de33bd97e0eQ47133066-9304f6ab-4417-0658-65ef-f33345cdfd15Q47263508-c774b861-49e4-e453-bb17-e0a936be878aQ48480090-4525939a-4020-a1ab-391a-b19dbb62f1e0Q49706804-162b2a7c-4bb4-4ea3-192d-994941e0b1e9Q50659098-6bd1da4e-494b-ad40-a7cd-a3b6769d9485Q53340358-d59b1a0f-4b86-d8c9-9eb0-61207401ba27
P50
description
Italian oncologist
@en
Italian oncologist
@en-ca
Italian oncologist
@en-gb
oncóloga italiana
@es
wetenschapper
@nl
طبيبة أورام إيطالية
@ar
name
Nicoletta Sacchi
@en
Nicoletta Sacchi
@nl
type
label
Nicoletta Sacchi
@en
Nicoletta Sacchi
@nl
prefLabel
Nicoletta Sacchi
@en
Nicoletta Sacchi
@nl
P21
P31
P496
0000-0002-7164-401X